NYSEAMERICAN:MAIA MAIA Biotechnology (MAIA) Stock Price, News & Analysis $1.13 +0.01 (+0.89%) As of 01:09 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsInsider TradesNews and TrendsOwnershipSEC Filings About MAIA Biotechnology Stock (NYSEAMERICAN:MAIA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MAIA Biotechnology alerts:Sign Up Key Stats Today's Range$1.10▼$1.1550-Day Range$1.12▼$1.4252-Week Range$0.87▼$3.19Volume209,158 shsAverage Volume761,978 shsMarket Capitalization$69.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview MAIA Biotechnology, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for cancer. The company’s research is centered on telomere biology, an area that seeks to exploit the mechanisms cancer cells use to maintain their ability to divide and survive. MAIA’s lead investigational product is atebimetostat, also known as THIO or 6-thio-2’-deoxyguanosine. The small-molecule therapy is designed to induce telomere dysfunction and promote the death of cancer cells. The company has evaluated atebimetostat in clinical studies involving patients with advanced non-small cell lung cancer, including research exploring its use following treatment with immune checkpoint inhibitors and in combination with immunotherapy. MAIA Biotechnology was founded in 2018 and is headquartered in Chicago, Illinois. The company has been led by co-founder Vladislav Sandler, who serves as chief executive officer. Its development activities are focused primarily on advancing atebimetostat and related telomere-targeting approaches for patients with difficult-to-treat solid tumors.AI Generated. May Contain Errors. Read More MAIA Biotechnology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks29th Percentile Overall ScoreMAIA MarketRank™: 1.434742767375 of 5 starsMAIA Biotechnology scored higher than 29% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for MAIA Biotechnology. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for MAIA Biotechnology are expected to grow in the coming year, from ($0.54) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MAIA Biotechnology is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MAIA Biotechnology is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMAIA Biotechnology has a P/B Ratio of 18.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MAIA Biotechnology's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.43% of the float of MAIA Biotechnology has been sold short.Short Interest Ratio / Days to CoverMAIA Biotechnology has a short interest ratio ("days to cover") of 3.43, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MAIA Biotechnology has recently increased by 28.20%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMAIA Biotechnology does not currently pay a dividend.Dividend GrowthMAIA Biotechnology does not have a long track record of dividend growth. News and Social Media2.0 / 5News SentimentN/A News SentimentMAIA Biotechnology has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.Search InterestOnly 1 people have searched for MAIA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows7 people have added MAIA Biotechnology to their MarketBeat watchlist in the last 30 days. This is an increase of 133% compared to the previous 30 days. Company Ownership4.3 / 5Insider TradingAcquiring Shares Cluster Insider Buying2 insiders have purchased shares of MAIA Biotechnology in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $352,426.00 in company stock, which represents 0.5029% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, MAIA Biotechnology insiders have bought more of their company's stock than they have sold. Specifically, they have bought $352,426.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders19.81% of the stock of MAIA Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions5.65% of the stock of MAIA Biotechnology is held by institutions.Read more about MAIA Biotechnology's insider trading history. Receive MAIA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MAIA Biotechnology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MAIA Stock News HeadlinesMAIA Completes THIO-101 Part C Enrollment; Phase 3 Enrollment Hits 65%October 7, 2026 | rttnews.comMAIA Biotechnology Achieves Patient Enrollment Milestones in Ongoing Phase 2 and Pivotal Phase 3 Clinical Trials in Non-Small Cell Lung CancerOctober 7, 2026 | globenewswire.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 15 at 1:00 AM | Investors Alley (Ad)MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Jumps 0.8% - What's Next?October 7, 2026 | americanbankingnews.comDiamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)October 1, 2026 | globenewswire.comMAIA Biotechnology, Inc. berichtet über Fortschritte in der zulassungsrelevanten Phase-3-Studie bei fortgeschrittenem nicht-kleinzelligem LungenkrebsSeptember 23, 2026 | de.marketscreener.comDVlad Vitoc Buys 73,000 Shares of MAIA Biotechnology (NYSEAMERICAN:MAIA) StockSeptember 16, 2026 | insidertrades.comInsider Buying: MAIA Biotechnology (NYSEAMERICAN:MAIA) Director Acquires $49,625.40 in StockSeptember 15, 2026 | insidertrades.comSee More Headlines MAIA Stock Analysis - Frequently Asked Questions How have MAIA shares performed this year? MAIA Biotechnology's stock was trading at $1.53 at the beginning of the year. Since then, MAIA shares have decreased by 25.8% and is now trading at $1.1350. How were MAIA Biotechnology's earnings last quarter? MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) released its earnings results on Monday, August, 10th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. How do I buy shares of MAIA Biotechnology? Shares of MAIA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MAIA Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some other companies that MAIA Biotechnology investors own include NVIDIA (NVDA), Tesla (TSLA), Energy Transfer (ET), Atlas Lithium (ATLX), Knightscope (KSCP), Palantir Technologies (PLTR) and SoundHound AI (SOUN). Company Calendar Last Earnings8/10/2026Today10/15/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (7m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 MAIA's financial health is in the Yellow zone, according to TradeSmith. MAIA has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSEAMERICAN:MAIA CIK1878313 Webwww.MAIABiotech.com Phone312-416-8592FaxN/AEmployees13Year FoundedN/AProfitability EPS (Trailing Twelve Months)($1.38) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$22.40 million Net MarginsN/A Pretax MarginN/A Return on Equity-211.15% Return on Assets-126.26% Debt Debt-to-Equity RatioN/A Current Ratio4.51 Quick Ratio4.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.06 per share Price / Book18.83Miscellaneous Outstanding Shares61,740,000Free Float49,511,000Market Cap$69.77 million OptionableNot Optionable Beta0.27 Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NYSEAMERICAN:MAIA) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MAIA Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MAIA Biotechnology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
